Article thumbnail

Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection

By Jennifer Hui-Chun Ho and Chuang-Ye Hong

Abstract

Salvianolic acids are the most abundant water-soluble compounds extracted from Radix Salvia miltiorrhiza (Danshen). In China, Danshen has been wildly used to treat cardiovascular diseases for hundreds of years. Salvianolic acids, especially salvianolic acid A (Sal A) and salvianolic acid B (Sal B), have been found to have potent anti-oxidative capabilities due to their polyphenolic structure. Recently, intracellular signaling pathways regulated by salvianolic acids in vascular endothelial cells, aortic smooth muscle cells, as well as cardiomyocytes, have been investigated both in vitro and in vivo upon various cardiovascular insults. It is discovered that the cardiovascular protection of salvianolic acids is not only because salvianolic acids act as reactive oxygen species scavengers, but also due to the reduction of leukocyte-endothelial adherence, inhibition of inflammation and metalloproteinases expression from aortic smooth muscle cells, and indirect regulation of immune function. Competitive binding of salvianolic acids to target proteins to interrupt protein-protein interactions has also been found to be a mechanism of cardiovascular protection by salvianolic acids. In this article, we review a variety of studies focusing on the above mentioned mechanisms. Besides, the target proteins of salvianolic acids are also described. These results of recent advances have shed new light to the development of novel therapeutic strategies for salvianolic acids to treat cardiovascular diseases

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3113734
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). Cardioprotection and matrix metalloproteinase-9 regulation of salvianolic acids on myocardial infarction in rats. Planta Med
  2. (2008). DA: Salvianolic acids prevent acute doxorubicin cardiotoxicity in mice through suppression of oxidative stress. Food Chem Toxicol
  3. (1990). Danshen–biology and its applications Beijing:
  4. (2008). G: A sensitive method for determination of salvianolic acid A in rat plasma using liquid chromatography/tandem mass spectrometry. Biomed Chromatogr
  5. (2009). GH: Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
  6. (2010). Guo DA: Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling.
  7. (2010). GW: Anti-inflammatory activity of salvianolic acid B in microglia contributes to its neuroprotective effect. Neurochem Res
  8. (1992). GZ: Protection by salvianolic acid A against adriamycin toxicity on rat heart mitochondria. Free Radic Biol Med
  9. (2010). Hong B: Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like highthroughput screening assay.
  10. (2005). HPLC determination and pharmacokinetic studies of salvianolic acid B in rat plasma after oral administration of Radix Salviae Miltiorrhizae extract. Biomed Chromatogr
  11. (2010). Huang YT: Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol Appl Pharmacol
  12. (2009). Isolation and purification of salvianolic acid A and salvianolic acid B from Salvia miltiorrhiza by high-speed counter-current chromatography and comparison of their antioxidant activity.
  13. (2006). JP: The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters. Carcinogenesis
  14. (2007). KH: New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev
  15. (2004). Liu JX: Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat. Planta Med
  16. (2010). Magnetic screening of the potential targeted protein of salvianolic acid B using T7 phage display library. Appl Biochem Biotechnol
  17. (2010). MS: Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell.
  18. (2005). MS: Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use.
  19. (2009). Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. Bioorg Med Chem Lett
  20. (2003). Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner.
  21. Salvianolic acid B attenuates brain damage and inflammation after traumatic brain injury in mice. Brain Res Bull .
  22. (2010). Salvianolic acid B attenuates hepatocyte apoptosis by regulating mediators in death receptor and mitochondrial pathways. Exp Biol Med (Maywood)
  23. (2001). SH2 domain inhibition: a problem solved? Curr Opin Chem Biol
  24. (1998). Shiao MS: Increase of Vitamin E Content in LDL and Reduction of Atherosclerosis in Cholesterol-Fed Rabbits by a Water-Soluble Antioxidant-Rich Fraction of Salvia miltiorrhiza. Arterioscler Thromb Vasc Biol
  25. (2006). SJ: Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta.
  26. (2004). SJ: The use of in vitro peptide-library screens in the analysis of phosphoserine/threonine-binding domain structure and function. Annu Rev Biophys Biomol Struct
  27. (2005). SQ: Salvianolic acid B attenuates plasminogen activator inhibitor type 1 production in TNF-alpha treated human umbilical vein endothelial cells.
  28. (2006). SQ: Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-alpha (TNF-alpha)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidasederived reactive oxygen species.
  29. (2007). Study on the mechanisms of an extract of Salvia miltiorrhiza on the regulation of permeability of endothelial cells exposed to tumour necrosis factor-alpha.
  30. (2005). TH: Determination and pharmacokinetic analysis of salvianolic acid B in rat blood and bile by microdialysis and liquid chromatography. J Chromatogr A
  31. (2006). Tsai TH: Bioavailability of salvianolic acid B in conscious and freely moving rats.
  32. (2009). X: Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways.
  33. (2009). YL: Proteomic screening of antioxidant effects exhibited by radix Salvia miltiorrhiza aqueous extract in cultured rat aortic smooth muscle cells under homocysteine treatment.
  34. (2007). YL: Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPStreated human aortic smooth muscle cells.
  35. (2001). YL: Salvianolic acid B attenuates VCAM-1 and ICAM-1 expression in TNF-alpha-treated human aortic endothelial cells.
  36. (1992). YW: Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem Pharmacol
  37. (2007). ZB: Chromatographic fingerprinting analysis of Danshen root (Salvia miltiorrhiza Radix et Rhizoma) and its preparations using high Ho and Hong
  38. (2005). ZH: Multi-component HPLC fingerprinting of Radix Salviae Miltiorrhizae and its LC-MS-MS identification. Chem Pharm Bull (Tokyo)
  39. (1995). Zhang JT: Protective effect of salvianolic acid a on ischemia-reperfusion induced injury in isolated rat heart. Yao Xue Xue Bao
  40. (2008). Zhao LB: Characterization of the radical scavenging and antioxidant activities of danshensu and salvianolic acid B. Food Chem Toxicol
  41. (2005). ZX: Aqueous extract of Salvia miltiorrhiza attenuates increased endothelial permeability induced by tumor necrosis factor-alpha. Int Immunopharmacol